pharma news

News

Data builds behind Bayer's Kerendia in kidney disease

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.

News

Yellow balloons with smiling faces drawn on them in black ink

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

News

GSK's RSV shot cleared in US for all adults

GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

News

Boy in a wheelchair looking out to the forest

Regenxbio, Solid report data with Duchenne gene therapies

Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta's Elevidys.

News

NHS hospitals 'should resist Palantir software rollout'

Hospitals in England have been told they do not have to deploy a controversial Palantir data platform by a coalition led by healthcare charity Medact.

News

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

Data builds behind Bayer's Kerendia in kidney disease

J&J says Inlexzo follow-up 'promising' in bladder cancer

GSK's RSV shot cleared in US for all adults

Regenxbio, Solid report data with Duchenne gene therapies

NHS hospitals 'should resist Palantir software rollout'

Immutep investors spooked by LAG-3 failure in lung cancer

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

pharma news

Editor's Picks